| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF470-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF801-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB801-SP | |||
| Carrier Free | MAB801-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 470-BC-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 801-CX-050/CF | |||
| Carrier Free | 801-CX-200/CF | |||
| Carrier Free | 801-CX-01M/CF | |||
| Carrier Free | 801-CX-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-16041SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB470-SP | |||
| Carrier Free | MAB470-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB4701-SP | |||
| Carrier Free | MAB4701-500 | |||
![N/A CXCL13/BLC/BCA-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL13_DCX130_ELISA_642.jpg "N/A CXCL13/BLC/BCA-1 [HRP]")
![N/A CXCL13/BLC/BCA-1 [HRP]](http://images.novusbio.com/fullsize2/CXCL13_DCX130_ELISA_72.jpg)
![N/A CXCL13/BLC/BCA-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL13_MCX130_ELISA_963.jpg "N/A CXCL13/BLC/BCA-1 [HRP]")
![N/A CXCL13/BLC/BCA-1 [HRP]](http://images.novusbio.com/fullsize2/CXCL13_MCX130_ELISA_258.jpg)
![N/A CXCL13/BLC/BCA-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL13_DY801_ELISA_2235.jpg "N/A CXCL13/BLC/BCA-1 [Biotin]")
![N/A CXCL13/BLC/BCA-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_CXCL13_DY470_ELISA_2051.jpg "N/A CXCL13/BLC/BCA-1 [Biotin]")
![Western Blot: CXCL13/BLC/BCA-1 Antibody [NBP2-16041] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with BCA1 antibody [N3C3] diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/CXCL13-BLC-BCA-1-Antibody-Western-Blot-NBP2-16041-img0017.jpg "Western Blot: CXCL13/BLC/BCA-1 Antibody [NBP2-16041] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with BCA1 antibody [N3C3] diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![Immunocytochemistry/Immunofluorescence: CXCL13/BLC/BCA-1 Antibody [NBP2-16041] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-CXCL13 at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CXCL13-BLC-BCA-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-16041-img0019.jpg)
![Immunohistochemistry-Paraffin: CXCL13/BLC/BCA-1 Antibody - BSA Free [NBP2-16041] - Human breast cancer tissue stained for CXCL13/BLC/BCA-1 (green) and counterstained with DAPI (blue). Alexa Fluor 488 version of antibody used (NBP2-16041AF488). Image from verified customer review.](http://images.novusbio.com/fullsize/CXCL13-BLC-BCA-1-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP2-16041-img0020.jpg)
![Western Blot: CXCL13/BLC/BCA-1 Antibody [NBP2-16041] - Non-transfected (-) and transfected (+) 293T whole cell extracts (60 ug) were separated by 15% SDS-PAGE, and the membrane was blotted with BCA1 antibody [N3C3] diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/CXCL13-BLC-BCA-1-Antibody-Western-Blot-NBP2-16041-img0015.jpg)
![Immunohistochemistry-Paraffin: CXCL13/BLC/BCA-1 Antibody [NBP2-16041] - Analysis of a FFPE tissue section of human esophageal carcinoma using 1:300 dilution of CXCL13 antibody (NBP2-16041). The signal was developed using HRP-DAB method which followed counterstaining of the cells with hematoxylin.](http://images.novusbio.com/fullsize/CXCL13-BLC-BCA-1-Antibody-Immunohistochemistry-Paraffin-NBP2-16041-img0018.jpg)
